晚期非小细胞肺癌免疫治疗进展  

Progress of immunotherapy for advanced non-small cell lung cancer

作　　者：刘树洪 王明军 林雨昕 韩佳欣 黄嘉炜 梁柱 何湛 王志刚 LIU Shuhong;WANG Mingjun;LIN Yuxin;HAN Jiaxin;HUANG Jiawei;LIANG Zhu;HE Zhan;WANG Zhigang(Guangdong Medical University,Zhanjiang 524023;Affiliated Hospital of Guangdong Medical University,Zhanjiang 524000,China)

机构地区：[1]广东医科大学,广东湛江524023 [2]广东医科大学附属医院,广东湛江524000

出　　处：《临床医学研究与实践》2021年第10期18-21,共4页Clinical Research and Practice

基　　金：2016年广东医科大学附属医院博士科研启动基金(No.BJ201602)。

摘　　要：肺癌是我国最常见的恶性肿瘤之一,其中非小细胞肺癌(NSCLC)约占85%,且大部分NSCLC患者在确诊时疾病已进展至晚期,病死率较高。近年来,临床对于晚期NSCLC的治疗已从传统的手术治疗、化学治疗、放射治疗、靶向治疗走向了免疫治疗。免疫检查点抑制剂(ICIs)治疗晚期NSCLC体现出了良好的抗肿瘤活性,尤其体现在细胞毒性T淋巴细胞相关抗原-4(CTLA-4)、程序性死亡受体-1(PD-1)、程序性死亡配体-1(PD-L1)抑制剂。基于此,本文将重点综述CTLA-4、PD-1、PD-L1抑制剂在晚期NSCLC中的治疗进展,以期提高患者的临床获益率,为临床选择合理治疗方案提供参考。Lung cancer is one of the most common malignant tumors in China,in which non-small cell lung cancer(NSCLC)accounts for about 85%.Most NSCLC patients'illness have advanced to the late stage of diagnosis and have a high mortality.In recent years,the clinical treatment of advanced NSCLC has changed from traditional surgery,chemotherapy,radiotherapy,targeted therapy to immunotherapy.Immune checkpoint inhibitors(ICIs)showed good antitumor activity in the treatment of advanced NSCLC,especially in the cytotoxic T lymphocyte associated antigen-4(CTLA-4),programmed death receptor-1(PD-1),programmed death ligand-1(PD-L1)inhibitors.Based on this,this paper focuses on the progress of CTLA-4,PD-1,PD-L1 inhibitors in the treatment of advanced NSCLC,in order to improve the clinical benefit rate of patients and provide reference for clinical selection of reasonable treatment.

关 键 词：非小细胞肺癌 免疫治疗 细胞毒T淋巴细胞相关抗原4 程序性死亡受体-1 程序性死亡配体-1 

分 类 号：R73[医药卫生—肿瘤] R97[医药卫生—临床医学]